Calliditas Therapeutics

Calliditas Therapeutics company information, Employees & Contact Information

Updated June 2026

Quick answer

Calliditas Therapeutics is a Pharmaceutical Manufacturing company and founded in 2004. It has approximately 237 employees on record. Contact data was last refreshed in June 2026. Find Calliditas Therapeutics's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Calliditas is a specialty pharmaceutical company developing high value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products.

Company Details

Employees
237
Founded
2004
Address
D5, Kungsbron 1, Stockholm,stockholm County,sweden
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Stockholm, Stockholm County
Looking for a particular Calliditas Therapeutics employee's phone or email?

Calliditas Therapeutics Questions

News

Welcome Calliditas Therapeutics • New Industrial partner in SweDeliver - Uppsala universitet

Welcome Calliditas Therapeutics • New Industrial partner in SweDeliver Uppsala universitet

New Biomarker, Subgroup Analyses of Phase 3 NefIgArd Trial for Budesonide - HCPLive

New Biomarker, Subgroup Analyses of Phase 3 NefIgArd Trial for Budesonide HCPLive

FDA grants full approval of Tarpeyo for IgA nephropathy - Healio

FDA grants full approval of Tarpeyo for IgA nephropathy Healio

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy - ScienceDirect.com

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy ScienceDirect.com

FDA Awards Full Approval to Budesonide (Tarpeyo) in Treatment of IgA Nephropathy - HCPLive

FDA Awards Full Approval to Budesonide (Tarpeyo) in Treatment of IgA Nephropathy HCPLive

FDA grants Calliditas Therapeutics Accelerated Approval of Tarpeyo - PharmaLive

FDA grants Calliditas Therapeutics Accelerated Approval of Tarpeyo PharmaLive

SweDeliver is all set for pole position - Uppsala universitet

SweDeliver is all set for pole position Uppsala universitet

Top Calliditas Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant